RT Journal Article
SR Electronic
T1 Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.09.20127050
DO 10.1101/2020.06.09.20127050
A1 Edward P. Gniffke
A1 Whitney E. Harrington
A1 Nicholas Dambrauskas
A1 Yonghou Jiang
A1 Olesya Trakhimets
A1 Vladimir Vigdorovich
A1 Lisa Frenkel
A1 D. Noah Sather
A1 Stephen E.P. Smith
YR 2020
UL http://medrxiv.org/content/early/2020/06/11/2020.06.09.20127050.abstract
AB High throughput serological tests that can establish the presence and functional activity of anti-SARS-COV2 antibodies are urgently needed. Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). First, we detected anti-spike-trimer IgGs in 22/24 and anti-spike-receptor-binding-domain (RBD) IgGs in 21/24 COVID+ subjects at a median of 36 (range 14-73) days following documented SARS-CoV-2 RNA (+) secretions. Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels. Depletion of trimer-reactive Igs from plasma reduced ACE2-trimer inhibitory capacity to a greater degree than depletion of RBD-reactive Igs, suggesting that inhibitory antibodies act by binding both within and outside of the RBD. Amongst the 24 subjects, presence of fever was associated with higher levels of anti-trimer IgG and inhibition of binding to human ACE2. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a COVID-19 research award from the University of Washington Institute for Translational Heath Sciences (via grant UL1 TR002319) and by a COVID19 award from the Research Integration Hub at Seattle Childrens Research Institute (to SEPS), by an NIH/NIAID K08 AI135072 and a Burroughs Wellcome Fund CAMS 1017213 grant (to WH), and by R01 AI140951 (to DNS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All parent protocols were approved by the Fred Hutchinson Cancer Research Center or Seattle Childrens IRBs. This study was conducted under a protocol approved by the Seattle Childrens IRB STUDY00002514 (SEPS).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are presented in the manuscript.